H.C. Wainwright analyst Andrew Fein lowered the firm’s price target on Keros Therapeutics (KROS) to $47 from $100 and keeps a Buy rating on the shares. The firm says the cibotercept clinical pause creates questions on the program’s viability. Given the announcement, the firm remains on the sidelines towards cibotercept creating any-near term value.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KROS:
- BofA cuts Keros target to $33, says ‘story still intact’ despite ‘setback’
- Keros Therapeutics downgraded to Hold from Buy at TD Cowen
- Keros Therapeutics downgraded to Market Perform from Outperform at William Blair
- Keros Therapeutics downgraded to Neutral from Buy at BTIG
- Morning Movers: Keros Therapeutics plummets after halting TROPOS trial dosing
Questions or Comments about the article? Write to editor@tipranks.com